TGFBR2 and neoplasm: For example, lentiviral delivery of shRNA against anti-inflammatory TGFbR2 in gastric cancer organoids led to metastatic differentiation and the acquisition of genetic heterogeneity, indicating that cancer-associated mutations in Tgfbr2 drive tumor progression [92].